High Response Rate and Corticosteroid Sparing with Arsenic Trioxide-Based First-Line Therapy in Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

Madan Jagasia, Hildegard Greinix, Mukta Arora et al. · Biology of Blood and Marrow Transplantation · 2014 · 5.4K citations · Full text

Life Sciences, Immunology, Immunopathology +9

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

Francesco Lo‐Coco, Giuseppe Avvisati, Marco Vignetti et al. · New England Journal of Medicine · 2013 · 1.6K citations · Full text

Medicine, Hematology, Oncology +17

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus

Hugues de Thé, Christine Chomienne, Michel Lanotte et al. · Nature · 1990 · 1.4K citations

Life Sciences, Genetics, Molecular Genetics +13

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

Alan K. Burnett, Nigel H. Russell, Robert K. Hills et al. · The Lancet Oncology · 2015 · 543 citations

Medicine, Hematology, Oncology +8

EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment

Hélène Schoemans, Stephanie J. Lee, James L.M. Ferrara et al. · Bone Marrow Transplantation · 2018 · 491 citations · Full text

Life Sciences, Hematology, Immunology +11